PATENT CLAIM ANALYSIS

Application Number: 16103226
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["424", "501000"]

Abstract:
The invention provides compositions comprising microparticles wherein the microparticles comprise at least one adenosine 2 a  receptor antagonist (A2ARA), at least one pharmaceutically acceptable polymer and at least one pharmaceutically acceptable negatively charged agent wherein the microparticles optionally have a highly negative zeta potential of less than about −40 mV. The invention also provides pharmaceutical compositions of the microparticles of the invention and methods of using the compositions of the invention to enhance an immune response in a patient in need thereof and as anti-cancer immunotherapy.

Claim (Index 5):
A method of enhancing an immune response in a patient in need thereof, said method comprising administering a therapeutically effective amount of an A2ARA microparticle composition of  claim 1  to a patient.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 96.0
- Lexical Diversity: 1.59649
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13878561', '09715902', '15393013', '15808534', '15458560']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6914204940212353
- 35 USC 102 Novelty (BERT): 0.4826696467257504
- Combined Prediction Score: 0.6705454092916868
- Mean Citation Score: 157.144396
- Max Citation Score: 161.34763
- Similarity Product: 108.47355660010876

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test